This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. VNRX, MYMD, NAVB, DCGO, BTMD, NKTX, ELDN, LNSR, PDEX, and CLLSShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include VolitionRx (VNRX), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), DocGo (DCGO), biote (BTMD), Nkarta (NKTX), Eledon Pharmaceuticals (ELDN), LENSAR (LNSR), Pro-Dex (PDEX), and Cellectis (CLLS). These companies are all part of the "medical" sector. Vermillion vs. Its Competitors VolitionRx MyMD Pharmaceuticals Navidea Biopharmaceuticals DocGo biote Nkarta Eledon Pharmaceuticals LENSAR Pro-Dex Cellectis VolitionRx (NYSE:VNRX) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Is VNRX or VRML more profitable? Vermillion has a net margin of -307.31% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Vermillion -307.31%-155.25%-103.47% Do institutionals & insiders believe in VNRX or VRML? 8.1% of VolitionRx shares are held by institutional investors. Comparatively, 18.1% of Vermillion shares are held by institutional investors. 10.4% of VolitionRx shares are held by company insiders. Comparatively, 4.4% of Vermillion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, VNRX or VRML? VolitionRx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, indicating that its stock price is 247% more volatile than the S&P 500. Do analysts prefer VNRX or VRML? VolitionRx currently has a consensus price target of $3.50, indicating a potential upside of 481.40%. Given VolitionRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe VolitionRx is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, VNRX or VRML? Vermillion has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.32M49.10-$35.32M-$0.25-2.41Vermillion$4.54M14.72-$15.24MN/AN/A Does the media prefer VNRX or VRML? In the previous week, VolitionRx's average media sentiment score of 0.00 equaled Vermillion'saverage media sentiment score. Company Overall Sentiment VolitionRx Neutral Vermillion Neutral SummaryVolitionRx beats Vermillion on 8 of the 14 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.82M$21.85M$5.77B$9.91BDividend YieldN/AN/A6.71%4.52%P/E Ratio-4.04N/A75.6126.09Price / Sales14.7218.48479.1187.80Price / CashN/AN/A36.9659.04Price / Book7.62N/A11.456.09Net Income-$15.24M-$19.12M$3.28B$266.32M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.69+50.4%N/A-54.2%$66.82M$4.54M-4.0443Gap DownVNRXVolitionRx2.0324 of 5 stars$0.66-3.7%$3.50+430.3%-16.0%$71.01M$1.32M-1.8380MYMDMyMD PharmaceuticalsN/A$0.07+9.6%N/AN/A$162KN/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010DCGODocGo2.5813 of 5 stars$1.65+0.6%$3.59+117.6%-56.6%$160.41M$435.97M-8.684,407Positive NewsBTMDbiote3.1712 of 5 stars$3.31+2.5%$6.00+81.3%-44.6%$159.69M$199.07M3.68194NKTXNkarta2.2763 of 5 stars$2.21+0.5%$13.60+515.4%-58.4%$156.25MN/A-1.49140News CoverageELDNEledon Pharmaceuticals2.0092 of 5 stars$2.62+1.9%$10.00+281.7%+5.4%$153.90MN/A-2.2410News CoveragePositive NewsAnalyst ForecastAnalyst RevisionLNSRLENSAR1.4622 of 5 stars$12.59-0.6%$15.00+19.1%+172.9%$151.09M$53.49M-2.99110Positive NewsPDEXPro-Dex2.7677 of 5 stars$46.71+1.1%$56.00+19.9%+70.9%$150.69M$53.84M16.68140News CoverageEarnings ReportGap DownCLLSCellectis2.225 of 5 stars$2.59-3.7%$4.00+54.4%+17.5%$149.52M$49.22M-3.16290Short Interest ↑ Related Companies and Tools Related Companies VolitionRx Competitors MyMD Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors DocGo Competitors biote Competitors Nkarta Competitors Eledon Pharmaceuticals Competitors LENSAR Competitors Pro-Dex Competitors Cellectis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: Musk’s IRS move could blindside your retirementElon Musk just made a bold financial move — one that some say could hit retirements harder than any recession....American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
